RSLS ReShape Lifesciences, Inc.: Likuiditas cepet

This chart of ReShape Lifesciences (RSLS) asset value demonstrates the quick ratio dynamics, which currently stands at 1.91. Management is pursuing stability in medtech by minimizing costs and revising the product line. Business revenues are based on the sale of Lap-Band systems and the development of new methods for combating obesity. The company's environmental profile focuses on safe waste recycling and the energy efficiency of its production facilities.

ReShape Lifesciences (RSLS) is facing a severe cash shortage due to the low return on investment of its medical developments. Under these conditions, the calculation model excludes slow-moving inventories, focusing exclusively on cash and accounts receivable. This methodology determines the business's ability to instantaneously cover short-term obligations without the fire sale of assets. An analysis of the absolute liquidity ratio allows for an assessment of bankruptcy risk as reserves are depleted.